Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Malignant Pleural Disease|Mesothelioma|Metastases|Lung Cancer|Breast Cancer
Interventions: GENETIC: iCasp9M28z T cell infusions|DRUG: cyclophosphamide|DRUG: pembrolizumab
Sponsor: Memorial Sloan Kettering Cancer Center
Collaborators: Bellicum Pharmaceuticals|United States Department of Defense